tiprankstipranks
MedWellAI (MWAI)
OTHER OTC:MWAI
US Market

MedWellAI (MWAI) AI Stock Analysis

66 Followers

Top Page

MWAI

MedWellAI

(OTC:MWAI)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 5.2)
Rating:45Neutral
Price Target:
$0.38
▼(-47.64% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance (volatile revenue, persistent heavy losses, ongoing cash burn, and negative equity). Technicals are also soft with the stock trading below major moving averages and negative MACD. Valuation provides limited offset given the negative P/E and lack of dividend data.
Positive Factors
Healthcare AI focus
MedWellAI operates squarely in healthcare AI, a durable secular market with rising demand for diagnostic and workflow automation. A focused product set aligned to provider pain points supports long-term adoption, clinical integration incentives, and structural revenue opportunities.
Negative Factors
Volatile revenue / sharp 2025 decline
A severe top-line drop and high revenue volatility undermine the core SaaS economics and make forecasting, R&D prioritization, and sales scalability difficult. Persistent revenue swings increase execution risk and delay the ability to demonstrate sustainable unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthcare AI focus
MedWellAI operates squarely in healthcare AI, a durable secular market with rising demand for diagnostic and workflow automation. A focused product set aligned to provider pain points supports long-term adoption, clinical integration incentives, and structural revenue opportunities.
Read all positive factors

MedWellAI (MWAI) vs. SPDR S&P 500 ETF (SPY)

MedWellAI Business Overview & Revenue Model

Company Description
MedWellAI Inc., through its subsidiary, develops, acquires, operates, and invests in businesses. It provides AI-driven healthcare and wellness solutions. The company also offers a B2B e-commerce platform for distributing pharmaceutical products, p...
How the Company Makes Money
MedWellAI generates revenue through a combination of subscription-based software-as-a-service (SaaS) licenses, one-time implementation fees, and ongoing support or consultation services for its AI-powered healthcare platforms. The company partners...

MedWellAI Financial Statement Overview

Summary
Overall financial condition is weak: revenue is highly volatile with a sharp 2025 decline, losses remain deep across periods, operating/free cash flow are negative in recent years, and the balance sheet shows negative shareholder equity (a key solvency risk) despite low absolute debt.
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue689.71K594.77K5.86M5.86M3.86M6.55M
Gross Profit585.91K586.67K1.93M1.93M1.16M931.01K
EBITDA-2.65M-2.87M-8.61M-21.59M1.07M-21.59M
Net Income-3.04M-3.61M-11.52M-11.52M-565.51K-22.43M
Balance Sheet
Total Assets549.87K805.50K3.94M6.59M16.28M13.36M
Cash, Cash Equivalents and Short-Term Investments223.22K401.31K57.81K258.00K490.28K2.10M
Total Debt600.30K604.27K500.00K500.00K385.44K19.15K
Total Liabilities7.61M3.14M7.81M7.10M5.69M4.40M
Stockholders Equity-7.06M-2.50M-3.87M-509.88K10.59M8.96M
Cash Flow
Free Cash Flow-861.21K-937.55K-4.13M-3.73M-9.88M-19.90M
Operating Cash Flow-861.21K-935.31K-4.13M-3.43M55.45K-1.57M
Investing Cash Flow247.90K1.19M4.17M4.17M-2.27M-9.12M
Financing Cash Flow0.000.00-243.15K-243.15K604.92K12.78M

MedWellAI Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.72
Price Trends
50DMA
0.44
Negative
100DMA
0.50
Negative
200DMA
0.53
Negative
Market Momentum
MACD
-0.02
Positive
RSI
44.36
Neutral
STOCH
66.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MWAI, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.44, and above the 200-day MA of 0.53, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of 66.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MWAI.

MedWellAI Risk Analysis

MedWellAI disclosed 12 risk factors in its most recent earnings report. MedWellAI reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MedWellAI Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
65
Neutral
$81.05M69.437.89%55.15%-22.92%
45
Neutral
$2.42M-1.21-85.65%35.68%
43
Neutral
$12.14M-0.3496.58%
43
Neutral
$13.87M-1.79-147.57%
39
Underperform
$1.32M-0.2819.01%44.24%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MWAI
MedWellAI
0.39
0.14
54.80%
NVNI
Nvni Group
1.21
-0.85
-41.26%
AIXI
Xiao-I Corp. ADR
0.10
-4.13
-97.68%
SPPL
Simpple Ltd.
1.87
-2.09
-52.78%
HIT
Health In Tech, Inc. Class A
1.42
0.74
108.82%
CSAI
Cloudastructure, Inc. Class A
0.57
-4.49
-88.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026